Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Salmonella's Sweet Tooth Predicts Its Downfall
For the first time UK scientists have shown what the food poisoning bug Salmonella feeds on to survive as it causes infection: glucose.

Cigarette Smoking Does Not Affect Everyone In Same Way
Cigarette smoking induced COPD, or chronic obstructive pulmonary disease, is a disease that results in severe breathing difficulty. According to World Health Organization (WHO) it is the fourth leading killer worldwide. However the mechanisms responsible for some smokers developing COPD and others evading the disease have not been well understood.
News of the day
Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL
Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infection in diabetic foot ulcers.
Diagnostics

Pharmalucence, Inc. Announces FDA Approval For Its Generic Sestamibi Kit

Pharmalucence, Inc., a leading supplier of radiopharmaceutical products, announced that it received approval from the U. S. Food and Drug Administration (FDA) Office of Generic Drugs for its Abbreviated New Drug Application (ANDA) to manufacture and market its Kit for the Preparation of Technetium Tc-99m Sestamibi Injection. The FDA has determined that Pharmalucence"s Sestamibi Kit is therapeutically equivalent to Cardiolite® 1, an imaging agent used in evaluating myocardial function and to detect coronary artery disease by localizing myocardial ischemia and infarction. The agent is also for use in breast imaging as a second line diagnostic after mammography to assist in the evaluation of breast lesions. Glenn Alto, President and CEO of Pharmalucence said, "When Pharmalucence was formed two years ago we committed to bring choice to the nuclear medicine community through an expanded line of radiopharmaceutical kits. The approval of our sestamibi kit marks the second generic imaging agent to emerge from the Pharmalucence Development team. Pharmalucence remains focused on delivering the products and enhancing the manufacturing assets that will provide nuclear medicine practitioners high quality imaging agents now and in the future." Pharmalucence will begin shipping their generic sestamibi kit on August 3. 1. Cardiolite® is a trademark of Lantheus Medical Imaging, Inc. Pharmalucence, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009